We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Spots Compared with Plasma Sample for Chitotriosidase Assay

By LabMedica International staff writers
Posted on 07 Jan 2014
Print article
Image: FP-6200 Series Spectrofluorometer (Photo courtesy of Jasco).
Image: FP-6200 Series Spectrofluorometer (Photo courtesy of Jasco).
The chitotriosidase enzyme is markedly elevated in plasma of patients with Gaucher's disease, a relatively common lysosomal storage disorder (LSD).

Chitotriosidase activity in plasma is also established as a therapeutic monitor for enzyme replacement therapy in Gaucher's patients and is under consideration to monitor therapy in other diseases such as Fabry disease, nephropathic cystinosis, and sarcoidosis.

Clinical biochemists at Cairo University (Giza, Egypt) compared blood spot samples with the corresponding plasma levels in 199 children of whom 56 were with confirmed diagnoses of 10 different lysosomal storage disorders, 73 normal controls, and 70 pathological controls. Several performance criteria such as limit of detection, linearity, within-run and day-to-day precision and sample stability were also evaluated.

Chitotriosidase activity in plasma and blood spot samples was measured using the substrate 4-methylumbelliferyl-β-D-N,N′,N″-triacetylchitotrioside (4-MU-C3) (Sigma-Aldrich; St. Louis, MO, USA). Fluorescence activity was measured with a FP 6200 spectrofluorometer, (Jasco; Tokyo, Japan) with excitation at 365 nm, and emission at 448 nm. Enzyme activities were calculated based on a calibration curve of 4-methylumbelliferone (4-MU) for each assay.

The calculated values for limit of detection were very comparable between the two methods: 2.7 and 2.0 nmol/mL/h for the plasma and blood spot assays, respectively. Similarly, the determined limits of quantification were 3.6 nmol/mL/h for plasma and 3.5 nmol/mL/h for blood spots. Although the precision using blood spots was inferior to plasma, it was quite acceptable for a blood spot method as the calculated limit of detection for blood spots was acceptable, looking at the wide range of the analytical spectrum. The plasma cutoff limit of 1,000 nmol/mL/h offered 100% sensitivity and 99% specificity for Gaucher's patients, while a blood spot cutoff limit of 400 nmol/mL/h offered 100% sensitivity and 97% specificity.

The authors concluded that blood spot sampling offers many advantages over traditional venous sampling. The level of agreement between blood spot and plasma chitotriosidase using the 4-MU-C3 substrate was found to be acceptable. Blood spot chitotriosidase is a clinically valid test. The study was published in the January 2014 issue of the journal Clinical Biochemistry.

Related Links:

Cairo University
Sigma-Aldrich
Jasco


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Piezoelectric Micropump
Disc Pump
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.